TrialMolecular oncology2021

Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).

Kazuko Sakai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.